The establishment of PD-1 inhibitor treatment prognosis model based on dynamic changes of peripheral blood indexes in patients with advanced lung squamous cell carcinoma.

Journal: Frontiers in oncology
Published Date: Dec 17, 2024

Abstract

BACKGROUND: Unlike patients with lung adenocarcinoma, patients with lung squamous cell carcinoma (LUSC) do not derive significant benefits from targeted therapy. In recent years, immunotherapy has revolutionized the treatment approach for LUSC. However, not all patients with this type of cancer respond to immunotherapy, necessitating the identification of effective biomarkers to predict survival prognosis and evaluate the efficacy of PD-1 inhibitors.

Authors

  • Yuyan Xie
    Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Hao Sun
    Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
  • Liying Shan
    Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Xin Ma
    Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Qingyu Sun
    Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Fang Liu
    The First Clinical Medical College of Gannan Medical University, Ganzhou 341000, Jiangxi Province, China.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals